Prognostic value of minimal residual disease measured by fusion‐gene transcript in infants with KMT2A‐rearranged acute lymphoblastic leukaemia treated according to the MLL‐Baby protocol. (14th February 2021)

• Record Type: Journal Article
• Authors: Tsaur, Grigory; Popov, Alexander; Riger, Tatiana; Kustanovich, Anatoly; Solodovnikov, Alexander; Shorikov, Egor; Demina, Anna; Verzhbitskaya, Tatiana; Streneva, Olga; Makarova, Olga; Lapotentova, Elena; Aleinikova, Olga; Miakova, Natalia; Boichenko, Elmira; Kondratchik, Konstantin; Ponomareva, Natalia; Karachunskiy, Alexander; Roumiantsev, Alexander; Fechina, Larisa
• Is Part Of: British journal of haematology. Volume 193:Number 6(2021)
• Page Start: 1151
• Page End: 1156
• Publication Date: 2021-02-14
• Subjects: acute lymphoblastic leukaemia -- fusion‐gene transcripts -- infants -- KMT2A -- minimal residual disease; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17304
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: The prognostic value of minimal residual disease (MRD) measured by fusion‐gene transcript (FGT) detection was investigated in 76 infants (aged ≤1 year) with acute lymphoblastic leukaemia (ALL) with lysine methyltransferase 2A ( KMT2A ) rearrangements. Either at the end of induction or at later time‐points, FGT‐MRD‐positivity was associated with poor outcome. FGT‐MRD‐positivity after first consolidation or first high‐risk block detected 46·5% of infants with extremely poor outcome [disease‐free survival (SE) 0·06 (0·06), cumulative incidence of relapse (SE) 0·91 (0·05)], which was also confirmed in multivariable analysis. Thus, FGT‐MRD measurement at a single time‐point clearly identifies infants with ALL who are curable with conventional chemotherapy and those who would benefit only from other treatment approaches.